Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 322

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

Open access
Kingsley, Gabrielle H., Kowalczyk, Anna, Taylor, Helen, Ibrahim, Fowzia, Packham, Jonathan C., McHugh, Neil J., Mulherin, Diarmuid M., Kitas, George D., Chakravarty, Kuntal, Tom, Brian D. M., O'Keeffe, Aidan G., Maddison, Peter J., Scott, David L. · 2012 · Rheumatology

Abstract

OBJECTIVE: MTX is widely used to treat synovitis in PsA without supporting trial evidence. The aim of our study was to test the value of MTX in the first large randomized placebo-controlled trial (RCT) in PsA. METHODS: A 6-month double-blind RCT compared MTX (15 mg/week) with placebo in active PsA. The primary outcome was PsA response criteria (PsARC). Other outcomes included ACR20, DAS-28 and their individual components. Missing data were imputed using multiple imputation methods. Treatments were compared using logistic regression analysis (adjusted for age, sex, disease duration and, where appropriate, individual baseline scores). RESULTS: Four hundred and sixty-two patients were screened and 221 recruited. One hundred and nine patients received MTX and 112 received placebo. Forty-four patients were lost to follow-up (21 MTX, 23 placebo). Twenty-six patients discontinued treatment (14 MTX, 12 placebo). Comparing MTX with placebo in all randomized patients at 6 months showed no significant effect on PsARC [odds ratio (OR) 1.77, 95% CI 0.97, 3.23], ACR20 (OR 2.00, 95% CI 0.65, 6.22) or DAS-28 (OR 1.70, 95% CI 0.90, 3.17). There were also no significant treatment effects on tender and swollen joint counts, ESR, CRP, HAQ and pain. The only benefits of MTX were reductions in patient and assessor global scores and skin scores at 6 months (P = 0.03, P < 0.001 and P = 0.02, respectively). There were no unexpected adverse events. CONCLUSIONS: This trial of active PsA found no evidence for MTX improving synovitis and consequently raises questions about its classification as a disease-modifying drug in PsA. Trial registration. Current Controlled Trials, www.controlled-trials.com, ISRCTN:54376151.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/rheumatology/kes001

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 322

Metadata

Authors
Kingsley, G. H., Kowalczyk, A., Taylor, H., Ibrahim, F., Packham, J. C., McHugh, N. J., Mulherin, D. M., Kitas, G. D., Chakravarty, K., Tom, B. D. M., O'Keeffe, A. G., Maddison, P. J., & Scott, D. L.
Venue
Rheumatology
Published
2012-02-17
Volume
51
Issue
8
Pages
1368-1377
ISSN
  • 1462-0324 (ISSN-L)
  • 1462-0332
OpenAlex
W2140020442
Cited by
322
References
43
FWCI
21.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. https://app.cochat.ai/papers/10.1093/rheumatology/kes001
The paper
Kingsley, G. H., Kowalczyk, A., Taylor, H., Ibrahim, F., Packham, J. C., McHugh, N. J., Mulherin, D. M., Kitas, G. D., Chakravarty, K., Tom, B. D. M., O'Keeffe, A. G., Maddison, P. J., & Scott, D. L. (2012). A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology. https://doi.org/10.1093/rheumatology/kes001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.